Enhancing Health: The Role of CD47 in Non-Cancer Diseases

Introduction to CD47 and Its Functions in Disease

CD47, a 50-kDa glycoprotein, is broadly expressed across human tissues and functions primarily as a “don’t eat me” signal. Its interaction with signal regulatory protein alpha (SIRPα) inhibits phagocytosis by macrophages, allowing cells, especially cancerous ones, to evade immune surveillance. While CD47’s role in cancer has garnered significant attention, emerging research indicates its potential therapeutic applications in various non-cancer diseases, including cardiovascular and neurodegenerative disorders, inflammatory diseases, and renal conditions. Understanding the multifaceted functions of CD47 can pave the way for innovative therapeutic strategies targeting these conditions.

Recent insights have revealed CD47’s involvement in regulating immune responses beyond cancer. It plays a role in the pathogenesis of diseases such as atherosclerosis, stroke, and autoimmune disorders by modulating phagocytosis, influencing T cell and macrophage function, and affecting cytokine secretion. As such, CD47-based therapies could provide novel avenues for treating diseases traditionally managed through other means.

CD47-Based Therapy for Atherosclerosis and Cardiovascular Health

Atherosclerosis is characterized by the accumulation of lipids, inflammatory cells, and fibrous elements in arterial walls, leading to plaque formation. High levels of CD47 have been identified in atherosclerotic plaques, suggesting that CD47 may be a therapeutic target in this context. Studies have shown that targeting CD47 can enhance macrophage-mediated clearance of apoptotic cells and debris within plaques, potentially stabilizing or even reversing atherosclerotic lesions (Deng et al., 2024).

Research involving CD47 blockade has demonstrated significant reductions in plaque size and necrotic core area in animal models. For instance, in Apoe−/− mice, administration of anti-CD47 antibodies resulted in decreased plaque burden and improved efferocytosis of apoptotic cells. This mechanism highlights the role of CD47 in promoting the inflammatory response associated with atherosclerosis and presents a compelling case for CD47 inhibitors in cardiovascular health.

Table 1: Effects of CD47-Based Therapies in Atherosclerosis

Impact of CD47 on Stroke and Neurodegenerative Disorders

Stroke, particularly intracerebral hemorrhage (ICH), remains a significant cause of morbidity and mortality globally. CD47 blockade has shown promise in enhancing the clearance of hematomas in experimental models of ICH. By promoting the phagocytosis of red blood cells (RBCs) and cellular debris by macrophages and microglia, CD47 inhibition may reduce secondary brain injury and improve neurological outcomes (Deng et al., 2024).

In studies involving models of experimental stroke, CD47 antagonists have been associated with reduced lesion volumes and improved functional recovery. These findings suggest that targeting the CD47-SIRPα axis could represent a novel therapeutic strategy for improving stroke outcomes.

CD47’s Role in Inflammatory Diseases and Autoimmunity

In conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), CD47 is implicated in the regulation of immune responses. Elevated CD47 expression has been observed in inflammatory tissues, where it may promote the survival of autoreactive cells and inhibit their clearance. CD47 blockade in murine models of autoimmune diseases has demonstrated decreased tissue inflammation and improved clinical outcomes (Deng et al., 2024).

Notably, therapies targeting CD47 have been shown to enhance macrophage phagocytosis of apoptotic cells in these settings, thereby reducing the accumulation of inflammatory cells and limiting tissue damage. This suggests that CD47-based therapies could have significant implications for treating various inflammatory and autoimmune conditions.

Therapeutic Applications of CD47 in Pulmonary and Renal Diseases

CD47 also plays a role in pulmonary diseases such as pulmonary hypertension (PH) and renal ischemia-reperfusion injury (RIRI). In PH, high levels of CD47 have been linked to impaired vasodilation and increased vascular resistance. CD47 inhibition has shown promise in restoring endothelial function and reducing pulmonary vascular remodeling (Deng et al., 2024).

In renal diseases, CD47 blockade has been associated with reduced tubular injury and improved recovery following ischemia-reperfusion events. By promoting the clearance of apoptotic cells and mitigating inflammatory responses, CD47-targeted therapies may enhance renal recovery and function post-injury.

Table 2: CD47 Therapeutic Applications in Non-Cancer Diseases

Future Directions for CD47 Research in Non-Cancer Treatments

Ongoing research is essential to fully elucidate the potential of CD47-based therapies across various non-cancer diseases. Future studies should focus on:

1. Mechanistic Insights: Understanding the precise molecular mechanisms by which CD47 regulates immune responses and tissue homeostasis.
2. Clinical Trials: Conducting well-designed clinical trials to evaluate the safety and efficacy of CD47-targeted therapies in non-cancer patient populations.
3. Combination Therapies: Exploring the potential of CD47 blockade in combination with other therapeutic modalities to enhance treatment outcomes in complex diseases.
4. Biomarker Development: Identifying biomarkers that can predict responses to CD47-based therapies and help tailor treatments to individual patients.

FAQ Section

What is CD47 and its main role in human health?

CD47 is a transmembrane protein that acts as a signal to inhibit phagocytosis by macrophages, effectively allowing cells to evade the immune system. It plays critical roles in various physiological processes, including tissue homeostasis and immune regulation.

How does CD47 relate to atherosclerosis?

In atherosclerosis, CD47 is often overexpressed in plaque regions, where it can inhibit the clearance of apoptotic cells and contribute to plaque instability. Targeting CD47 has been shown to enhance phagocytosis and may reduce the burden of atherosclerotic disease.

Can CD47-blocking therapies be used for stroke treatment?

Yes, studies suggest that CD47 blockade can enhance the clearance of hematomas in stroke models, potentially leading to better neurological outcomes. This approach is still under investigation.

Are there any side effects associated with CD47-based therapies?

As with any therapeutic intervention, potential side effects exist, particularly concerning immune modulation. Further clinical trials are needed to understand the safety profile of CD47-targeted therapies.

What is the future of CD47 research in non-cancer diseases?

Future research on CD47 is focused on understanding its mechanisms in various diseases, developing clinical applications, and exploring combination therapies that enhance its therapeutic potential.

References

1. Deng, W.-Q., Ye, Z.-H., Tang, Z., Zhang, X.-L., & Lu, J.-J. (2024). Beyond cancer: The potential application of CD47-based therapy in non-cancer diseases. Acta Pharm Sin B, 14(11), 2045–2062. https://doi.org/10.1016/j.apsb.2024.11.018

2. Lutsenko, S., Roy, S., & Tsvetkov, P. (2024). Mammalian copper homeostasis: physiological roles and molecular mechanisms. Physiol Rev, 104(2), 687–726

3. Krenzlin, H., Wesp, D. M. A., Korinek, A. A. E., Ubbens, H., Volland, J., Masomi-Bornwasser, J., Weber, K. J., & Mole, D. (2024). Effects of Argon in the Acute Phase of Subarachnoid Hemorrhage in an Endovascular Perforation Model in Rats. Neurocrit Care, 40(1), 1–12. https://doi.org/10.1007/s12028-024-02090-3

4. Increased Plasma Levels of Thrombin-Cleaved Osteopontin in Patients with Delayed Cerebral Infarction After Aneurysmal Subarachnoid Hemorrhage. Int J Mol Sci, 26(6), 2781. https://doi.org/10.3390/ijms26062781

5. Characteristics, diagnostic accuracy, and safety in patients receiving selective prehospital thrombolysis in out-of-hospital cardiac arrest: A retrospective cohort study. Acta Pharm Sin B, 14(1), 10–20. https://doi.org/10.1016/j.resplu.2025.100909

6. Fungal Sinusitis Spreading to the Sellar Region Mimicking a Pituitary Tumor: Case Report and Literature Review. J Fungi, 11(3), 233. https://doi.org/10.3390/jof11030233